The Rest Of Mea Wearable Injectors Market was valued at $55.1 Million in 2025 and projected to reach to $84.9 Million by 2030, representing a compound annual growth rate of 9.1%. The Rest Of Mea wearable injectors market is positioned for sustained growth through 2030, supported by increasing healthcare infrastructure investments and rising awareness of advanced drug delivery technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Mea wearable injectors market is projected to grow from $55.1 million in 2025 to $84.9 million by 2030, representing significant expansion in the region's advanced drug delivery infrastructure.
The Rest Of Mea region demonstrates a 9.1% CAGR through 2030, driven by increasing healthcare investments and growing adoption of innovative injection technologies across emerging markets.
Rising healthcare expenditure across Rest Of Mea countries is accelerating the adoption of wearable injector systems, supporting modernization of drug delivery mechanisms in the region.
Rest Of Mea is experiencing steady expansion in wearable injector adoption, reflecting growing demand for patient-centric, convenient drug delivery solutions across diverse healthcare settings.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Develops the Libertas wearable injector platform for subcutaneous delivery of large-volume and high-viscosity biologics and biosimilars, with 2–5 mL and 5–10 mL configurations. | Prefilled, ready-to-use design | Hands-free drug delivery | Simplified administration and reduced preparation errors |
|
|
Offers the MiniMed 780G automated insulin delivery system, which integrates an insulin pump with continuous glucose monitoring to automatically adjust insulin delivery based on glucose levels. | Automated insulin delivery | Continuous glucose monitoring integration | Improved diabetes management |
|
|
Offers the Neulasta Onpro kit, an on-body injector that delivers pegfilgrastim after chemotherapy, allowing the dose to be administered approximately 27 hours after application. | At-home drug administration | Reduced need for next-day clinic visits | Convenient post-chemotherapy treatment |
|
|
Offers SKYRIZI with an on-body injector for subcutaneous administration of risankizumab for eligible patients with conditions including Crohn's disease and ulcerative colitis. | Convenient biologic administration | Supports home-based treatment | Reduced administration burden |
|
|
Develops the Omnipod range of tubeless, wearable insulin delivery systems, including Omnipod 5, which integrates automated insulin delivery technology for diabetes management. | Tubeless, wearable insulin delivery | Automated diabetes management | Greater convenience for daily insulin therapy |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INFECTIOUS DISEASES (Therapeutic Application) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 10.8% from 2025 to 2030 |
| Largest Segment | DISPOSABLE (Usage) |
| Market Size Base Year (Billions) | ~USD 11.32 (2025) |
| Revenue Forecast (Billions) | ~USD 18.91 (2030) |
| Segments Covered | Type, Delivery Method, End User, Formulation End User, Technology, Therapeutic Application, Usage, Product, Device End User |
9 segment dimensions are covered across the global market.
Rest Of Mea's wearable injectors market is estimated at $55.1 million in 2025, with expectations to reach $84.9 million by 2030.
Rest Of Mea's wearable injectors market is projected to grow at a compound annual growth rate of 9.1% from 2025 to 2030.
Rest Of Mea's market growth is driven by increasing chronic disease prevalence, improving healthcare infrastructure, regulatory framework enhancements, and rising pharmaceutical investments in the region.
Rest Of Mea's market is experiencing strong demand in biologics and specialty pharmaceuticals, particularly for chronic disease management and self-administered therapies.
Rest Of Mea is attracting global device manufacturers through strategic partnerships with local healthcare providers, enabling market penetration and improved accessibility across the region.
This study used both primary and secondary sources extensively. The research examined factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and key players' strategies.
This research study used comprehensive secondary sources: directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and companies' SEC filings. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the wearable injectors market. It was also used to identify key market players and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources on the supply side include project/sales/marketing/business development managers; presidents; CEOs; vice presidents; chairpersons; chief operating officers; chief strategy officers; directors; chief information officers; and chief medical information officers related to the wearable injectors market. Primary demand-side sources include healthcare professionals from hospitals, nursing care facilities, long-term health centers, and ambulatory surgery centers.

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million
To know about the assumptions considered for the study, download the pdf brochure
The total size of the wearable injectors market was determined by triangulating data from three approaches, as described below. After each approach, we calculated a weighted average of the three approaches based on the level of assumptions used in each.

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, where applicable, to complete the overall market engineering process and arrive at accurate statistics for all segments and subsegments.
The wearable injectors market refers to drug delivery devices that are designed to administer large-volume biologics or medications subcutaneously over an extended period, typically ranging from minutes to hours. These compact, lightweight, body-worn devices improve patient compliance by enabling self-administration outside clinical settings, particularly for chronic conditions such as diabetes, oncology, autoimmune disorders, and cardiovascular diseases. Wearable injectors are engineered to deliver high-viscosity drugs safely and accurately with minimal discomfort, reducing the need for frequent hospital visits and manual injections. The market encompasses a wide range of device types, including on-body and off-body injectors, bolus injectors, and patch pumps, powered by electromechanical or mechanical systems.
Based on the provided market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
Company Information
Geographic Analysis
Competitive Landscape Assessment
Full forecast, segment splits, and company analysis for all Wearable Injectors Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report